Kappa Bioscience is expanding its business in the United States.
The company established a US-based entity in late 2020. “Our strategy requires focusing on one of the world’s largest regions for dietary supplements and functional foods. We have reached the point where the number of clients and projects require dedicated local resources,” said Jörg Büttinghaus, VP of Sales at Kappa Bioscience Group, and President of Kappa’s US business.
Egil Greve, CEO at Kappa Bioscience, said: “Through our New Jersey-based entity, Kappa Ingredients USA, we are investing in customer centricity, business development, and marketing. In a second step, we will expand our local production. Our objective is to support our clients to a faster and greater degree with products to fit the local needs, made in the USA and to create new jobs and partnerships. One great example is our scientific cooperation with US universities and research institutes, to develop further scientific evidence of the many health benefits of vitamin K2 MK-7.”
The company has also implemented organisational changes. Following Dominik Mattern`s arrival (ex-Lonza) as VP of Marketing, Jörg Büttinghaus will spearhead sales. With his industrial expertise, Kappa will be able to expand local focus in the US. The company will intensify its collaboration with US distributors and expand its offerings.
Thies Ripcke has taken over operational management in the US. Justin Theriault, who joined Kappa back in 2017, will continue to manage key customers. Continuing to invest in the US, Kappa has been expanding the team with experienced managers including Crystal Webber, MS Food Biochemistry and Registered Dietitian (ex AIDP, PLT, Ajinomoto), Jennifer Chase, MS Food Science (ex PHM, Frutarom, LifeVantage), and Tamara Sofi, MS Holistic Nutrition (ex-Lycored, Designs For Health).
“Kappa Bioscience is well poised for explosive growth internationally, and I am excited to lead our expansion efforts,“ said Egil Greve.
